AbbVie Q1 FY26: where the revenue came from and where it went
The whole income statement of AbbVie for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- May 8, 2026
Revenue$15.0B
+12% year over year
Gross profit$10.8B
72% margin
Operating profit$4.0B
27% margin
Net profit$0.7B
5% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 15.0 | 100% | +12% |
| Skyrizi | 4.5 | 30% | +31% |
| Neuroscience | 2.9 | 19% | +26% |
| Rinvoq | 2.1 | 14% | +23% |
| Oncology | 1.6 | 11% | +0% |
| Aesthetics | 1.2 | 8% | +8% |
| Other revenue | 1.0 | 7% | |
| Other key products | 1.0 | 7% | +23% |
| Humira | 0.7 | 4% | −39% |
| Cost of revenue | −4.2 | 28% | |
| Gross profit | 10.8 | 72% margin | +2pp |
| SG&A | −3.6 | 24% | −1pp |
| Other | −3.2 | 21% | |
| Operating profit | 4.0 | 27% margin | −1pp |
| Interest & other costs | −3.0 | ||
| Tax | −0.3 | ||
| Net profit | 0.7 | 5% margin | −5pp |
181 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest